Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease

Young Hak Kim, Seong Wook Park, Seung Whan Lee, Duk Woo Park, Sung Cheol Yun, Cheol Whan Lee, Myeong Ki Hong, Hyun Sook Kim, Jae Ki Ko, Jae Hyeong Park, Jae Hwan Lee, Si Wan Choi, In Whan Seong, Yoon Haeng Cho, Nae Hee Lee, June Hong Kim, Kook Jin Chun, Seung Jung Park

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

BACKGROUND - Outcomes remain relatively unfavorable for stent-based coronary intervention of lesions with long diseased segments. This study compared sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) for long coronary lesions. METHODS AND RESULTS - The present randomized, multicenter, prospective study compared the use of long (≥32 mm) SES with PES in 500 patients with long (≥25 mm) native coronary lesions. The primary end point of the trial was the rate of binary in-segment restenosis according to follow-up angiography at 6 months. The SES and PES groups had similar baseline characteristics. Lesion length was 33.9±11.6 mm in the SES group and 34.5±12.6 mm in the PES group (P=0.527). The in-segment binary restenosis rate was significantly lower in the SES group than in the PES group (3.3% versus 14.6%; relative risk 0.23; P<0.001). In-stent late loss of lumen diameter was 0.09±0.37 mm in the SES group and 0.45±0.55 mm in the PES group (P<0.001). In patients with restenoses, a pattern of focal restenosis was more common in the SES group than in the PES group (100% versus 53.3%, P=0.031). Consequently, SES patients had a lower rate of target-lesion revascularization at 9 months (2.4% versus 7.2%, P=0.012). The incidence of death (0.8% in SES versus 0% in PES, P=0.499) or myocardial infarction (8.8% in SES versus 10.8% in PES, P=0.452) at 9 months of follow-up was not statistically different between the 2 groups. CONCLUSIONS - For patients with long native coronary artery disease, SES implantation was associated with a reduced incidence of angiographic restenosis and a reduced need for target-lesion revascularization compared with PES implantation.

Original languageEnglish
Pages (from-to)2148-2153
Number of pages6
JournalCirculation
Volume114
Issue number20
DOIs
Publication statusPublished - 2006 Nov 1

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease'. Together they form a unique fingerprint.

  • Cite this

    Kim, Y. H., Park, S. W., Lee, S. W., Park, D. W., Yun, S. C., Lee, C. W., Hong, M. K., Kim, H. S., Ko, J. K., Park, J. H., Lee, J. H., Choi, S. W., Seong, I. W., Cho, Y. H., Lee, N. H., Kim, J. H., Chun, K. J., & Park, S. J. (2006). Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation, 114(20), 2148-2153. https://doi.org/10.1161/CIRCULATIONAHA.106.666396